VYNE Therapeutics Inc. (VYNE) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VYNE Revenue Growth
Revenue Breakdown (FY 2025)
VYNE's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
VYNE Revenue Analysis (2015–2025)
As of May 8, 2026, VYNE Therapeutics Inc. (VYNE) generated trailing twelve-month (TTM) revenue of $570,000, reflecting explosive growth of +54.8% year-over-year. The most recent quarter (Q4 2025) recorded $130,000 in revenue, down 23.1% sequentially.
Looking at the longer-term picture, VYNE's 5-year compound annual growth rate (CAGR) stands at -51.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $21.0 million in 2020.
Revenue diversification analysis shows VYNE's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including DERM (-27.4% YoY), PRGO (-3.6% YoY), and SKIN (-8.2% YoY), VYNE has outperformed the peer group in terms of revenue growth. Compare VYNE vs DERM →
VYNE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VYNECurrent | $570,000 | +54.8% | -51.4% | -5219.1% | |
 DERM | $56M | -27.4% | +10.0% | -24.4% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% | |
 ORGO | $564M | +12.1% | +10.8% | 10.0% | |
 GDRX | $797M | -1.2% | +7.7% | 13.4% |
VYNE Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $570K | +13.8% | $547K | 96.0% | $-29,749,000 | -5219.1% |
| 2024 | $501K | +18.2% | $501K | 100.0% | $-43,637,000 | -8710.0% |
| 2023 | $424K | -11.1% | $424K | 100.0% | $-29,258,000 | -6900.5% |
| 2022 | $477K | -48.8% | $477K | 100.0% | $-34,295,000 | -7189.7% |
| 2021 | $931K | -95.6% | $931K | 100.0% | $-38,911,000 | -4179.5% |
| 2020 | $21.0M | +4638.8% | $19.6M | 93.4% | $252.5M | 1203.0% |
| 2019 | $443K | -95.8% | $93K | 21.0% | $-76,242,000 | -17210.4% |
| 2018 | $10.6M | +132.2% | $10.6M | 100.0% | $-54,535,000 | -512.5% |
| 2017 | $4.6M | +579.8% | $4.6M | 100.0% | $-29,593,000 | -645.9% |
| 2016 | $674K | - | $674K | 100.0% | $-14,332,000 | -2126.4% |
See VYNE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VYNE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VYNE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVYNE — Frequently Asked Questions
Quick answers to the most common questions about buying VYNE stock.
Is VYNE's revenue growth accelerating or slowing?
VYNE revenue is accelerating at +54.8% year-over-year, exceeding the 5-year CAGR of -51.4%. TTM revenue reached $570000.00. Growth momentum has increased versus prior periods.
What is VYNE's long-term revenue growth rate?
VYNE Therapeutics Inc.'s 5-year revenue CAGR of -51.4% reflects the sustained expansion pattern. Current YoY growth of +54.8% is above this long-term average.
How is VYNE's revenue distributed by segment?
VYNE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.